St Jude Medical study shows cost-effectiveness of PressureWire

St Jude Medical has announced data from a clinical study that highlights the practical benefits provided by its coronary intervention technology PressureWire.

Cost utility analysis data from the Fame II trial showed that fractional flow reserve-guided treatment using PressureWire was cost-effective for coronary interventions when compared to the best available medical therapy.

While the initial cost of this treatment method is higher, this gap quickly narrowed over time due to the reduction in the number of hospital readmissions among PressureWire patients.

Other data from Fame II shows that this type of therapy can also improve patient outcomes and quality-of-life indicators, such as freedom from angina and chest pain.

Frank Callaghan, president of the cardiovascular and ablation technologies division at St Jude Medical, said: "Today's cost-effectiveness analysis adds to the body of evidence in support of PressureWire technology to improve patient outcomes while delivering value."

Earlier this month, the firm reported positive data from a separate study that demonstrated the potential upsides of using peripheral nerve stimulation in the treatment of chronic migraines.